Mission of KMWSH‑ORC‑TR

The mission of KMWSH‑ORC‑TR is to serve as the operational and commercial backbone for technology transfer initiatives originating from the SAMANSIC Coalition. Its core purpose is to de‑risk, validate, and scale intellectual property‑based projects by subjecting them to real‑world pilot testing before they are spun off into dedicated commercial entities such as KMWSH‑ICA. The company operates on a principle of evidence‑driven commercialization: no technology is transferred to the market without first demonstrating technical feasibility, regulatory compliance, and financial viability through controlled pilot projects.

​

Roles of KMWSH‑ORC‑TR

​

1. Pilot Project Evaluation and Validation

Since its establishment in 2019, KMWSH‑ORC‑TR has functioned as a specialized technology transfer evaluator. Its primary role is to design, fund, and manage pilot projects that test the real‑world performance of emerging technologies. For example, the UAM and drone infrastructure project underwent feasibility studies from 2022 to 2023 under the supervision of KMWSH‑ORC‑TR, partnering with Royal NLR and PT IAMI. The company’s evaluation framework includes technical benchmarks, market demand analysis, regulatory gap assessment, and financial modeling. Only those pilots that meet predetermined success criteria are advanced to full commercialization.

​

2. Legal and Corporate Infrastructure Provider

KMWSH‑ORC‑TR holds the official legal registration in Türkiye under the full name KMWSH ENDÜSTRİYEL PROJE SANAYİ VE TİCARET LİMİTED ŞİRKETİ. This grants it the authority to enter into binding contracts, own or license intellectual property, employ staff, open bank accounts, and conduct international trade. When a new entity like KMWSH‑ICA is created, KMWSH‑ORC‑TR provides the initial legal scaffolding, including:

​

• Drafting and signing partnership agreements, such as the irrevocable pledge with the Canadian inventor.

• Securing regulatory approvals and certifications.

• Holding interim IP rights until they are formally transferred to the spin‑off company.

• Managing compliance with Turkish commercial law, including tax and corporate governance.

 

3. Commercialization Arm of the SAMANSIC Coalition

The SAMANSIC Coalition is a collaborative network that funds and guides technology development through intellectual property‑based partnerships rather than traditional equity or debt. KMWSH‑ORC‑TR acts as the Coalition’s execution vehicle in the marketplace. Its role includes:

​

• Converting Coalition‑owned IP into marketable products and services.

• Negotiating licensing and dual‑brand agreements, for instance with DermaCure for the Four‑Pillar nutraceutical protocol.

• Managing cross‑border trade logistics between production sites in Türkiye and Egypt and target markets in Indonesia, Canada, and the United States.

• Distributing revenue shares back to Coalition members according to pre‑set IP ownership percentages.

 

4. Direct Operational Partner to KMWSH‑ICA

Once KMWSH‑ICA is registered as a private joint‑stock company, KMWSH‑ORC‑TR will serve as its direct operational partner. This means:

​

• KMWSH‑ORC‑TR provides ongoing project management services, including supply chain coordination, quality assurance, and regulatory liaison.

• It holds the master agreements with key suppliers, such as GMP‑certified manufacturers in Indonesia and cold chain logistics providers, and subcontracts those services to KMWSH‑ICA.

• It acts as a guarantor for KMWSH‑ICA’s obligations during the early operational phase until the new company establishes its own credit and trading history.

• It ensures continuity of the KMWSH asset model—Knowledge, Motivation, Wisdom, Sustainability, and Honesty—by auditing KMWSH‑ICA’s compliance with ethical and transparency standards.

 

5. Risk Mitigation and Phased Spin‑Off Facilitator

One of the most critical roles of KMWSH‑ORC‑TR is to absorb initial operational risk so that spin‑off entities like KMWSH‑ICA are born with a proven track record. By the time KMWSH‑ICA is registered in late 2026, the following risks will have already been managed by KMWSH‑ORC‑TR:

​

• Technological risk, validated through successful pilot projects.

• Market risk, established through letters of intent or pre‑sales agreements.

• Legal risk, resolved via irrevocable pledges and regulatory clearances.

• Counterparty risk, locked in through long‑term partnership agreements.

 

This phased approach means that investors in KMWSH‑ICA are not funding research and development or market testing. Instead, they are funding the scaling and revenue acceleration of already‑de‑risked opportunities.

​

Conclusion

In essence, KMWSH‑ORC‑TR is the foundation and engine room of the entire technology transfer ecosystem. Its mission is to ensure that no technology moves from the laboratory or coalition agreement to the open market without rigorous, real‑world pilot validation. Its roles span legal sheltering, commercial execution, coalition representation, risk absorption, and phased spin‑off facilitation. By the time KMWSH‑ICA is registered, KMWSH‑ORC‑TR will have already completed the high‑risk work, leaving the new company free to focus exclusively on revenue generation and market expansion.